The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction

被引:101
作者
Goldstein, Irwin [1 ]
Burnett, Arthur L. [2 ]
Rosen, Raymond C. [3 ]
Park, Peter W. [4 ]
Stecher, Vera J. [4 ]
机构
[1] Alvarado Hosp, Sexual Med, 5555 Reservoir Dr,Suite 300, San Diego, CA 92120 USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[3] HealthCore New England Res Inst, Watertown, MA USA
[4] Pfizer Inc, New York, NY USA
关键词
Erectile Dysfunction; Impotence; Nitric Oxide; Sildenafil; Clinical Trials; NITRIC-OXIDE; CORPUS CAVERNOSUM; INTERNATIONAL INDEX; PENILE PROSTHESIS; RISK-FACTORS; MEN; CITRATE; VALIDATION; RELAXATION; PHOSPHODIESTERASE-5;
D O I
10.1016/j.sxmr.2018.06.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The serendipitous discovery of sildenafil (Viagra [sildenafil citrate]) as a treatment for erectile dysfunction (ED) is one of the most fascinating drug development stories of our time. When sildenafil was approved by the U.S. Food and Drug Administration in 1998, it revolutionized the treatment protocol for men with ED, once considered a psychological issue or an inevitable part of aging. Aim: To review the discovery of sildenafil and its role in changing the field of sexual medicine in the context of the epidemiology and history of treatment for ED. Methods: For this narrative review, a literature search was conducted to identify essential articles and was supplemented by author observations from a historical perspective. Main Outcome Measure: A broad overview of ED and its past, current, and future treatments. Results: ED is a prevalent condition for which medical treatment had been limited to genitally localized interventions, including surgery, vacuum pumps, injectable therapies, and intraurethral suppositories. The discovery of sildenafil provided a safe, oral pharmacotherapy for the treatment of ED, sparking greater understanding of the science behind ED and its role in men's overall health. Conclusion: The approval of sildenafil initiated a global conversation about ED that had profound implications for patients, methods of clinical practice, and academic sexual medicine. These changes will catalyze continued advances in ED treatment. Copyright (C) 2018, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:115 / 128
页数:14
相关论文
共 103 条
  • [1] Agency MaHPR, MHRA RECL VIAGR CONN
  • [2] EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction
    Althof, SE
    Corty, EW
    Levine, SB
    Levine, F
    Burnett, AL
    McVary, K
    Stecher, V
    Seftel, AD
    [J]. UROLOGY, 1999, 53 (04) : 793 - 799
  • [3] American Association of Retired Persons, 1999, AARP MOD MAT SEX STU
  • [4] [Anonymous], 2001, VIAGRA SILDENAFIL CI
  • [5] [Anonymous], 1999, INT J IMPOT RES, V11, P70
  • [6] Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation
    Blount, MA
    Beasley, A
    Zoraghi, R
    Sekhar, KR
    Bessay, EP
    Francis, SH
    Corbin, JD
    [J]. MOLECULAR PHARMACOLOGY, 2004, 66 (01) : 144 - 152
  • [7] Sildenafil, a novel effective oral therapy for male erectile dysfunction
    Boolell, M
    GepiAttee, S
    Gingell, JC
    Allen, MJ
    [J]. BRITISH JOURNAL OF UROLOGY, 1996, 78 (02): : 257 - 261
  • [8] Boolell M, 1996, Int J Impot Res, V8, P47
  • [9] Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999
    Boshier, A
    Wilton, LV
    Shakir, SAW
    [J]. BJU INTERNATIONAL, 2004, 93 (06) : 796 - 801